188 related articles for article (PubMed ID: 37956967)
21. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
22. Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Oppolzer IA; Riester J; Büttner R; Burger M; Schnabel MJ
Int Urol Nephrol; 2023 Aug; 55(8):1943-1949. PubMed ID: 37271776
[TBL] [Abstract][Full Text] [Related]
23. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
24. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
25. The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis.
Mei T; Wang T; Deng Q; Gong Y
Front Immunol; 2023; 14():1062679. PubMed ID: 36825025
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis.
Lu J; Li L; Lan Y; Liang Y; Meng H
Cancer Med; 2019 Dec; 8(18):7503-7515. PubMed ID: 31679184
[TBL] [Abstract][Full Text] [Related]
27. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
29. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
30. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
32. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
33. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Zhang W; Gu J; Bian C; Huang G
Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
[No Abstract] [Full Text] [Related]
34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
35. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
36. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
38. Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis.
Wang S; Yan L; Yu J; Lu C
Eur Arch Otorhinolaryngol; 2024 Feb; ():. PubMed ID: 38358507
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort.
Kotwal A; Rouleau SG; Dasari S; Kottschade L; Ryder M; Kudva YC; Markovic S; Erickson D
J Investig Med; 2022 Apr; 70(4):939-946. PubMed ID: 34969937
[TBL] [Abstract][Full Text] [Related]
40. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.
Mazarico I; Capel I; Giménez-Palop O; Albert L; Berges I; Luchtenberg F; García Y; Fernández-Morales LA; De Pedro VJ; Caixàs A; Rigla M
J Endocrinol Invest; 2019 Dec; 42(12):1443-1450. PubMed ID: 31093955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
